Boston Scientific Corporation (BSX) Income Statement
BSX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsBSX revenue and net income
Where BSX's revenue goes
2025Each bar shows an amount and its share of revenue. BSX kept 14.4% of revenue as net income.
BSX profit margins
BSX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +19.9% | +16.5% | +15.2% | +10.4% |
| Gross profit | +34.9% | +21.5% | +20.0% | +11.7% |
| Operating income | +50.7% | +29.6% | +45.9% | +17.5% |
| Net income | +55.7% | +60.5% | — | — |
| EPS (diluted) | +21.5% | +21.3% | +26.0% | +12.6% |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
BSX quarterly EPS vs estimates
Boston Scientific beat the analyst EPS estimate in 8 of the last 8 quarters. Next report: October 28, 2026 (estimate $0.76).
BSX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.07B | $16.75B | $14.24B | $12.68B | $11.89B | $9.91B | $10.73B | $9.82B | $9.05B | $8.39B |
| Cost of revenue | $6.22B | $6.48B | $5.41B | $4.97B | $4.43B | $4.34B | $3.86B | $3.35B | $3.18B | $3.04B |
| Gross profit | $13.85B | $10.27B | $8.83B | $7.71B | $7.46B | $5.58B | $6.88B | $6.48B | $5.87B | $5.34B |
| Research & development | $2.05B | $1.61B | $1.41B | $1.32B | $1.20B | $1.14B | $1.17B | $1.11B | $997.0M | $920.0M |
| Sales, general & admin | $6.89B | $5.98B | $4.97B | $4.52B | $4.36B | $3.79B | $3.94B | $3.57B | $3.29B | $3.10B |
| Total operating expenses | $9.88B | $7.63B | $6.65B | $5.89B | $5.54B | $4.97B | $5.17B | $4.74B | $4.35B | $4.11B |
| Operating income | $3.97B | $2.63B | $2.18B | $1.82B | $1.92B | $601.0M | $1.71B | $1.74B | $1.52B | $1.24B |
| Interest income | $349.0M | $107.0M | $22.0M | $470.0M | $341.0M | $361.0M | $30.0M | $3.0M | $5.0M | $5.0M |
| Interest expense | $349.0M | $387.0M | $272.0M | $464.0M | $349.0M | $468.0M | $513.0M | $269.0M | $230.0M | $234.0M |
| Income before taxes | $3.38B | $2.28B | $1.99B | $1.14B | $1.08B | −$79.0M | $687.0M | $1.42B | $933.0M | $177.0M |
| Income taxes | $493.0M | $436.0M | $393.0M | $443.0M | $36.0M | $2.0M | −$4.01B | −$249.0M | $828.0M | −$170.0M |
| Net income | $2.89B | $1.85B | $1.59B | $698.0M | $1.04B | −$82.0M | $4.70B | $1.67B | $104.0M | $347.0M |
| EBITDA | $5.10B | $3.94B | $3.45B | $2.74B | $2.52B | $1.51B | $2.21B | $2.58B | $2.01B | $1.23B |
| EPS (diluted) | $3.05 | $2.51 | $2.05 | $1.71 | $1.63 | $0.96 | $1.59 | $1.48 | $1.26 | $1.12 |
| Gross margin | 69.0% | 61.3% | 62.0% | 60.8% | 62.8% | 56.2% | 64.1% | 65.9% | 64.9% | 63.7% |
| Operating margin | 19.8% | 15.7% | 15.3% | 14.4% | 16.2% | 6.1% | 15.9% | 17.7% | 16.9% | 14.7% |
| Net margin | 14.4% | 11.1% | 11.2% | 5.5% | 8.7% | −0.8% | 43.8% | 17.0% | 1.1% | 4.1% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.44B | $5.20B | $5.29B | $5.07B | $5.06B | $4.66B | $4.56B | $4.21B | $4.12B | $3.86B | $3.73B | $3.53B |
| Cost of revenue | $1.59B | $1.59B | $1.35B | $1.52B | $1.64B | $1.71B | $1.89B | $1.56B | $1.53B | $1.47B | $1.41B | $1.36B |
| Gross profit | $3.85B | $3.61B | $3.94B | $3.54B | $3.42B | $2.95B | $2.67B | $2.65B | $2.58B | $2.38B | $2.31B | $2.17B |
| Research & development | $554.0M | $516.0M | $569.0M | $514.0M | $526.0M | $443.0M | $460.0M | $407.0M | $383.0M | $366.0M | $363.0M | $356.0M |
| Sales, general & admin | $1.80B | $1.78B | $1.83B | $1.74B | $1.72B | $1.60B | $1.61B | $1.56B | $1.45B | $1.36B | $1.38B | $1.24B |
| Total operating expenses | $2.67B | $2.54B | $2.73B | $2.49B | $2.60B | $2.05B | $2.08B | $1.97B | $1.84B | $1.74B | $1.75B | $1.61B |
| Operating income | $1.18B | $1.07B | $1.21B | $1.05B | $819.0M | $896.0M | $589.0M | $674.0M | $747.0M | $644.0M | $558.0M | $558.0M |
| Interest income | — | — | $90.0M | $99.0M | $90.0M | $82.0M | $164.0M | $83.0M | — | — | — | $66.0M |
| Interest expense | $96.0M | $90.0M | $90.0M | $87.0M | $90.0M | $87.0M | $139.0M | $83.0M | $81.0M | $72.0M | $67.0M | $67.0M |
| Income before taxes | $1.06B | $1.16B | $700.0M | $939.0M | $941.0M | $805.0M | $585.0M | $668.0M | $420.0M | $608.0M | $505.0M | $609.0M |
| Income taxes | $155.0M | −$176.0M | $31.0M | $183.0M | $146.0M | $133.0M | $23.0M | $200.0M | $98.0M | $115.0M | $1.0M | $105.0M |
| Net income | $907.0M | $1.34B | $668.0M | $755.0M | $793.0M | $674.0M | $566.0M | $469.0M | $324.0M | $494.0M | $504.0M | $504.0M |
| EBITDA | $1.51B | $1.60B | $1.16B | $1.37B | $1.37B | $1.22B | $1.07B | $1.06B | $812.0M | $984.0M | $885.0M | $976.0M |
| EPS (diluted) | $0.86 | $0.80 | $0.80 | $0.75 | $0.75 | $0.75 | $0.70 | $0.63 | $0.62 | $0.56 | $0.55 | $0.50 |
| Gross margin | 70.7% | 69.4% | 74.5% | 69.9% | 67.7% | 63.3% | 58.6% | 62.9% | 62.7% | 61.8% | 62.1% | 61.4% |
| Operating margin | 21.6% | 20.6% | 22.8% | 20.7% | 16.2% | 19.2% | 12.9% | 16.0% | 18.1% | 16.7% | 15.0% | 15.8% |
| Net margin | 16.7% | 25.7% | 12.6% | 14.9% | 15.7% | 14.5% | 12.4% | 11.1% | 7.9% | 12.8% | 13.5% | 14.3% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in BSX's financial statements (latest annual report filed February 17, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
BSX financial results
In fiscal year 2025 (ended December 31, 2025), Boston Scientific reported revenue of $20.1 billion, up 19.9% from the year before. It had net income of $2.9 billion (up 55.7%), a net profit margin of 14.4%. Diluted earnings per share came to $3.05. Over five years revenue grew at an average rate of 15.2% a year.
See the BSX stock overview for the latest quote and news, or the BSX chart for price history and technical indicators.
BSX income statement FAQ
What is Boston Scientific's annual revenue?
Boston Scientific reported total revenue of $20.1 billion for fiscal year 2025, which ended on December 31, 2025. That was up 19.9% from $16.7 billion the previous year.
Is Boston Scientific profitable?
Yes. Boston Scientific reported net income of $2.9 billion in fiscal 2025, a net profit margin of 14.4%; its operating margin was 19.8%.
What is Boston Scientific's gross margin?
Boston Scientific's gross margin was 69.0% in fiscal 2025: for every $100 of revenue, Boston Scientific kept $69 after the direct cost of its products and services.
How much does Boston Scientific spend on research and development?
Boston Scientific spent $2.1 billion on research and development in fiscal 2025, 10.2% of revenue.
How fast is Boston Scientific growing?
Revenue grew 15.2% a year on average over the last five fiscal years, from $9.9 billion to $20.1 billion.
What are Boston Scientific's earnings per share?
Boston Scientific earned $3.05 per diluted share in fiscal 2025, compared with $2.51 a year earlier.
When will Boston Scientific report its next earnings?
Boston Scientific is expected to report results for the quarter ending September 30, 2026 on October 28, 2026 before the market opens.
When does Boston Scientific's fiscal year end?
Boston Scientific's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 17, 2026.